Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Novus Therapeutics Inc (NVUS)

Novus Therapeutics Inc (NVUS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,970
  • Shares Outstanding, K 1,436
  • Annual Sales, $ 0 K
  • Annual Income, $ -16,010 K
  • 60-Month Beta 1.92
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.73
Trade NVUS with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -15.06
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/16/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -3.60
  • Number of Estimates 1
  • High Estimate -3.60
  • Low Estimate -3.60
  • Prior Year -3.24
  • Growth Rate Est. (year over year) -11.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.61 +7.27%
on 12/28/20
23.99 -39.14%
on 12/10/20
-7.54 (-34.06%)
since 12/04/20
3-Month
13.61 +7.27%
on 12/28/20
27.32 -46.56%
on 10/30/20
-1.60 (-9.88%)
since 10/02/20
52-Week
4.50 +224.44%
on 03/20/20
27.32 -46.56%
on 10/30/20
+3.62 (+32.97%)
since 01/03/20

Most Recent Stories

More News
Acute Otitis Media Treatment Market Share Expected Huge Growth during 2020-2027

An increase in cases of acute otitis media is driving the global acute otitis media treatment and management market. Other factors such as an increase in young maternal age, children with aboriginal ancestry,...

ABT : 126.79 (-0.51%)
BAYRY : 13.2900 (-1.41%)
LLY : 230.10 (-0.41%)
GSK : 38.93 (-0.46%)
NVS : 83.48 (-1.07%)
NVUS : 14.60 (-5.19%)
OTIC : 1.7500 (+7.36%)
PDP.VN : 0.300 (+1.69%)
PFE : 43.89 (-1.30%)
Novus Therapeutics Announces Name Change to Eledon Pharmaceuticals; Provides Corporate Update and Outlook

Eledon to commence trading on the Nasdaq exchange under the ticker "ELDN" effective tomorrow, January 5, 2021

NVUS : 14.60 (-5.19%)
Novus Therapeutics Announces Results of Special Meeting of Stockholders

Novus Therapeutics, Inc. ("Novus") (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation,...

NVUS : 14.60 (-5.19%)
Novus Therapeutics Appoints June Lee, M.D., to Board of Directors

Novus Therapeutics, Inc. ("Novus") (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation,...

MYOK : 224.91 (+0.05%)
NVUS : 14.60 (-5.19%)
Novus Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 16, 2020 / Novus Therapeutics, Inc. (NVUS) (NASDAQ:NVUS) will be discussing their earnings results in their call to be held on November 16, 2020 at 4:30 PM Eastern...

NVUS : 14.60 (-5.19%)
Novus Therapeutics Reports Third Quarter 2020 Financial Results

Novus Therapeutics, Inc. ("Novus") (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation,...

NVUS : 14.60 (-5.19%)
Novus Therapeutics to Release Third Quarter 2020 Financial Results on Monday, November 16

Novus Therapeutics, Inc. ("Novus") (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation,...

NVUS : 14.60 (-5.19%)
Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis

Novus Therapeutics, Inc. ("Novus") (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation,...

NVUS : 14.60 (-5.19%)
Moving Average Crossover Alert: Novus Therapeutics

Novus Therapeutics is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

NVUS : 14.60 (-5.19%)
Novus Therapeutics Announces One-for-Eighteen Reverse Stock Split

Novus Therapeutics, Inc. (NASDAQ : NVUS) today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a reverse stock split of its issued...

NVUS : 14.60 (-5.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Novus Therapeutics, Inc. is a pharmaceutical company. It focused on the acquisition, development and commercialization of ear, nose and throat products. The company's platform consists of OP-01 Foam Platform and OP-02 Surfactant Program. Novus Therapeutics, Inc., formerly known as Tokai Pharmaceuticals...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 16.16
1st Resistance Point 15.38
Last Price 14.60
1st Support Level 14.21
2nd Support Level 13.82
3rd Support Level N/A

See More

52-Week High 27.32
Fibonacci 61.8% 18.60
Fibonacci 50% 15.91
Last Price 14.60
Fibonacci 38.2% 13.22
52-Week Low 4.50

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar